12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cetrorelix pamoate: Phase III data

Top-line data from the double-blind, European Phase III Z-036 trial in 420 patients showed that cetrorelix pamoate missed the primary endpoint of absolute change in IPSS from baseline to week 52 vs. placebo. Cetrorelix pamoate also missed all secondary endpoints vs. placebo, including significant improvements in quality of life measures, maximum and mean uroflow volume and residual volume. Aeterna Zentaris said...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >